Literature DB >> 31710871

Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.

Yosuke Kamiya1, Tomoyuki Fujisawa2, Masato Kono3, Hidenori Nakamura3, Koshi Yokomura4, Naoki Koshimizu5, Mikio Toyoshima6, Shiro Imokawa7, Hiromitsu Sumikawa8, Takeshi Johkoh9, Hideki Yasui1, Hironao Hozumi1, Yuzo Suzuki1, Masato Karayama1, Kazuki Furuhashi1, Noriyuki Enomoto1, Yutaro Nakamura1, Naoki Inui10, Takafumi Suda1.   

Abstract

OBJECTIVE: Interstitial lung disease (ILD) is a condition characterized by a higher mortality rate in primary Sjögren's syndrome (pSS). However, factors influencing the outcome of patients with pSS-associated ILD remain unclear. The aim of the present study was to evaluate predictive factors associated with a worse prognosis in pSS-ILD.
METHODS: This retrospective study included 99 consecutive patients with pSS-ILD. Clinical characteristics, laboratory findings, and pulmonary function tests at the time of diagnosis were analyzed. Chest HRCT images were reviewed by two experienced chest radiologists. Prognostic factors were assessed by univariate and multivariate analyses, using Cox proportional hazards regression model.
RESULTS: Median age was 68 years (73% women). In the total patient population, the 5- and 10-year survival rates were 89.8% and 79.0%, respectively. Univariate analysis revealed a significant association between prognosis and age, serum Krebs von den Lungen-6 (KL-6) levels, and %FVC. None of the chest HRCT findings were related to patient outcomes. Based on multivariate analyses adjusted by age and gender, lower levels of %FVC and higher levels of KL-6 were significantly associated with poor outcomes. Using optimal cutoff levels, according to receiver operating characteristic curve analyses, KL-6 > 800 U/mL were significantly associated with worse prognosis (HR: 2.91, 95% CI: 1.04-8.10). Patients with elevated serum KL-6 levels (>800 U/mL) showed a higher mortality rate than those without elevated serum KL-6 levels (p = 0.02).
CONCLUSIONS: Lower %FVC and higher serum KL-6 levels are predictive factors for poor outcome in patients with pSS-ILD.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Forced vital capacity; Interstitial lung disease; KL-6; Prognostic factors; Sjörgen's syndrome

Year:  2019        PMID: 31710871     DOI: 10.1016/j.rmed.2019.105811

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Sjogren's Syndrome and Pulmonary Disease.

Authors:  Ruben A Peredo; Scott Beegle
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.

Authors:  Yu-Hsiang Chiu; Chen-Chih Chu; Chun-Chi Lu; Feng-Cheng Liu; Shin-En Tang; Shi-Jye Chu; San-Yuan Kuo; Hsiang-Cheng Chen
Journal:  J Inflamm Res       Date:  2022-04-08

3.  Risk factors for progression of interstitial lung disease in Sjögren's syndrome: a single-centered, retrospective study.

Authors:  Shi-Hao He; Yu-Jie He; Kuang-Jin Guo; Xu Liang; Shan-Shan Li; Tian-Fang Li
Journal:  Clin Rheumatol       Date:  2021-11-10       Impact factor: 2.980

4.  Blood KL-6 predicts prognosis in primary Sjögren's syndrome-associated interstitial lung disease.

Authors:  Yun Jae Kim; Jooae Choe; Su-Jin Moon; Jin Woo Song
Journal:  Sci Rep       Date:  2022-03-29       Impact factor: 4.379

5.  Interstitial lung disease in Primary Sjögren's syndrome.

Authors:  Wei Lin; Zhifei Xin; Jianlong Zhang; Ning Liu; Xiuying Ren; Meilu Liu; Yashuang Su; Yixuan Liu; Liu Yang; Shaoying Guo; Yupeng Yang; Yang Li; Jingjing Cao; Xiaoran Ning; Jingjing Li; He Xue; Nannan Niu; Yingmin Chen; Fang Li; Lijun Sun; Xiaopeng Zhang; Fengxiao Zhang; Wen Zhang
Journal:  BMC Pulm Med       Date:  2022-02-27       Impact factor: 3.317

6.  Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

Authors:  Eric L Matteson; Clive Kelly; Jörg H W Distler; Anna-Maria Hoffmann-Vold; James R Seibold; Shikha Mittoo; Paul F Dellaripa; Martin Aringer; Janet Pope; Oliver Distler; Alexandra James; Rozsa Schlenker-Herceg; Susanne Stowasser; Manuel Quaresma; Kevin R Flaherty
Journal:  Arthritis Rheumatol       Date:  2022-05-02       Impact factor: 15.483

Review 7.  Sjögren's Syndrome-Related Organs Fibrosis: Hypotheses and Realities.

Authors:  Margherita Sisto; Domenico Ribatti; Sabrina Lisi
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

8.  Biomarkers of interstitial lung disease associated with primary Sjögren's syndrome.

Authors:  Lin Weng; Yaqiong Chen; Tao Liang; Yihua Lin; Dehao Liu; Ciyong Yu; Yudi Hu; Wei Lui; Yongliang Liu; Xiangfang Chen; Qiyuan Li; Shengxiang Ge; Dana P Ascherman; Juan Chen
Journal:  Eur J Med Res       Date:  2022-10-10       Impact factor: 4.981

9.  Long-term clinical course and outcome in patients with primary Sjögren syndrome-associated interstitial lung disease.

Authors:  Yun Jae Kim; Jooae Choe; Ho Jeong Kim; Jin Woo Song
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

10.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Authors:  Tao Zhang; Ping Shen; Chunyan Duan; Lingyun Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.